Merz Pharmaceuticals GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merz Pharmaceuticals GmbH
The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.
J&J’s entry into the kidney stone management market will not threaten Boston Scientific’s leadership position in that market in the near-term, according to Wells Fargo analyst Larry Biegelsen.
- Other Names / Subsidiaries
- BioteCon Therapeutics GmbH
- Cabochon Aesthetics, Inc.
- ON Light Sciences, Inc.
- Ulthera, Inc.
- Merz Pharmaceuticals GmbH
- Merz Pharma France
- Merz North America, Inc.
- Merz Pharma (Schweiz) Ag
- Merz Pharma GmbH